FDA lifts clinical hold following review of Company’s Complete Response submission. Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites. Early data suggests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results